Supplemental Tables and Figures

Supplemental Table 1:

Grade 3/4 Adverse Events During Protocol Therapy All Evaluable Patients (CTCAE Version 4.0)

Adverse Event	Arm 1 IV Carboplatin + IV Paclitaxel N = 95 n(%)	Arm 2 IP Cisplatin + IV/IP Paclitaxel N = 67 n(%)	Arm3 IP Carboplatin + IV/IP Paclitaxel N = 92 n(%)
Febrile Neutropenia	5(5)	1(1)	1(1)
Sinus Tachycardia	0	0	1(1)
Hearing Impaired	1(1)	0	1(1)
Abdominal Distention	0	1 (1)	1(1)
Abdominal Pain	1(1)	4(6)	2(2)
Ascites	0	0	1(1)
Constipation	0	1(1)	0
Diarrhea	2(2)	0	0
Nausea	0	2(3)	0
Vomiting	0	2(3)	2(2)
Fatigue	4(4)	1(1)	0
Infusion Site Extravasation	0(0)	1 (1)	0(0)
Infusion related reaction	0	0	1 (1)
Abdominal infection	0	1 (1)	0
Pelvic infection	0	1 (1)	0
Other infections and infestations	0	1 (1)	0
Pain	2(2)	0(0)	0
Allergic Reaction	1(1)	0	0
GGT Increased	0	0	1(1)
Hyperglycemia	1(1)	0	0
Hypokalemia	0	2(3)	0
Obesity	1(1)	0	0
Back Pain	1(1)	1(1)	0
Generalized Muscle Weakness	0	1(1)	0
Dizziness	0	1(1)	0
Peripheral Sensory Neuropathy	0	1(1)	0
Syncope	1(1)	2(3)	1(1)
Vasovagal reaction	1 (1)	0	
Genital Tract Fistula	2(2)	0	0
Vaginal fistula	1 (1)	0	0
Pelvic pain	0	1 (1)	0
Other Reproductive System Disorder	0	0	1(1)
Dyspnea	0	0	3(3)
Flushing	0	0	1(1)
Hypertension	3(3)	1(1)	3(3)
Thromboembolic Event	2(2)	1(1)	2(2)

Supplemental Figure 1:

Analysis of Quality of Life Response: EORTC QLQ-C30